{"id":716635,"date":"2024-10-15T08:56:01","date_gmt":"2024-10-15T08:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=716635"},"modified":"2024-10-15T08:56:01","modified_gmt":"2024-10-15T08:56:01","slug":"alpha1-antitrypsin-deficiency-pipeline-dynamics-2024-fda-approvals-therapeutic-advances-moa-roa-by-delveinsight-apic-bio-dicerna-pharma-peak-bio-arrowhead-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alpha1-antitrypsin-deficiency-pipeline-dynamics-2024-fda-approvals-therapeutic-advances-moa-roa-by-delveinsight-apic-bio-dicerna-pharma-peak-bio-arrowhead-pharma_716635.html","title":{"rendered":"Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1728932353.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1728932353.png\" alt=\"Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Alpha-1 Antitrypsin Deficiency pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2024<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Alpha-1 Antitrypsin Deficiency Pipeline Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Companies across the globe are diligently working toward developing novel Alpha-1 Antitrypsin Deficiency treatment therapies with a considerable amount of success over the years. Alpha-1 Antitrypsin Deficiency Key players such as &#8211; <strong>Apic Bio, Dicerna Pharmaceuticals, Peak Bio, Arrowhead Pharmaceuticals, and others,<\/strong> are developing therapies for the Alpha-1 Antitrypsin Deficiency treatment&nbsp;<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Alpha-1 Antitrypsin Deficiency Emerging therapies such as &#8211; <strong>APB-101, Belcesiran, PHP 303, ARO-AAT, and others<\/strong> are expected to have a significant impact on the Alpha-1 Antitrypsin Deficiency market in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li>\n<p><strong>In April 2024, Wave Life Sciences Ltd. (Nasdaq: WVE)<\/strong>, a clinical-stage biotechnology company dedicated to harnessing the potential of RNA medicines to transform human health, today announced the approval of its first clinical trial application (CTA) for the RestorAATion-2 trial of WVE-006. This is the company&rsquo;s first-in-class RNA editing oligonucleotide, being developed to treat alpha-1 antitrypsin deficiency (AATD). WVE-006 is GalNAc-conjugated and administered subcutaneously, without the use of a lipid nanoparticle (LNP) delivery system.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2024, Enlivex Therapeutics<\/strong> has announced promising topline safety and efficacy results from its Phase II clinical trial of Allocetra, an off-the-shelf cell therapy for sepsis. The randomized, placebo-controlled trial aims to identify the optimal dose of Allocetra when administered in conjunction with the standard care for sepsis caused by different infections.<\/p>\n<\/li>\n<li>\n<p><strong>In July 2023, Grifols<\/strong> successfully achieved the enrollment goal of 339 participants for the Phase III trial known as the Study of ProlAstin-c Randomized Therapy with Alpha-1 augmentation (SPARTA), which aims to address emphysema. This placebo-controlled, double-blind, randomized study is structured to evaluate the safety and effectiveness of two doses of Alpha1-Proteinase inhibitor Prolastin-C&mdash;60mg\/kg and 120mg\/kg&mdash;administered once weekly in comparison to a placebo. The primary objective is to assess whether these doses can slow down the progression of lung tissue loss in patients with emphysema.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alpha-1 Antitrypsin Deficiency Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by a deficiency or malfunction of alpha-1 antitrypsin (AAT) protein, which is produced primarily in the liver. AAT is important for protecting the lungs from damage caused by enzymes produced by white blood cells, specifically neutrophil elastase.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Alpha-1 Antitrypsin Deficiency Market Forecast, Size &amp; Share Analysis Report:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Alpha-1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intra-articular<\/p>\n<\/li>\n<li>\n<p>Intraocular<\/p>\n<\/li>\n<li>\n<p>Intrathecal<\/p>\n<\/li>\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Ophthalmic<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<li>\n<p>Transdermal<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oligonucleotide<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Alpha-1 Antitrypsin Deficiency Assessment by Product Type<\/p>\n<\/li>\n<li>\n<p>Alpha-1 Antitrypsin Deficiency By Stage and Product Type<\/p>\n<\/li>\n<li>\n<p>Alpha-1 Antitrypsin Deficiency Assessment by Route of Administration<\/p>\n<\/li>\n<li>\n<p>Alpha-1 Antitrypsin Deficiency By Stage and Route of Administration<\/p>\n<\/li>\n<li>\n<p>Alpha-1 Antitrypsin Deficiency Assessment by Molecule Type<\/p>\n<\/li>\n<li>\n<p>Alpha-1 Antitrypsin Deficiency by Stage and Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Alpha-1 Antitrypsin Deficiency Report covers around 4+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<li>\n<p>Route of Administration<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Alpha-1 Antitrypsin Deficiency product details are provided in the report. Download the Alpha-1 Antitrypsin Deficiency pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Alpha-1 Antitrypsin Deficiency therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Alpha-1 Antitrypsin Deficiency Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>APB-101: Apic Bio<\/p>\n<\/li>\n<li>\n<p>Belcesiran: Dicerna Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>PHP 303: Peak Bio<\/p>\n<\/li>\n<li>\n<p>ARO-AAT: Arrowhead Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alpha-1 Antitrypsin Deficiency Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Alpha-1 Antitrypsin Deficiency pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights about companies that are developing therapies for the Alpha-1 Antitrypsin Deficiency treatment with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li>\n<p>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha-1 Antitrypsin Deficiency Treatment.<\/p>\n<\/li>\n<li>\n<p>Alpha-1 Antitrypsin Deficiency key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Alpha-1 Antitrypsin Deficiency Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha-1 Antitrypsin Deficiency market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Alpha-1 Antitrypsin Deficiency drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Alpha-1 Antitrypsin Deficiency Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Increasing investment in the R&amp;D activities for developing novel therapeutics<\/p>\n<\/li>\n<li>\n<p>Rise in awareness among people<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alpha-1 Antitrypsin Deficiency Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Lack of diagnostic methods<\/p>\n<\/li>\n<li>\n<p>Treatment dosage being poorly standardized<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Alpha-1 Antitrypsin Deficiency Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Coverage: Global<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Key Alpha-1 Antitrypsin Deficiency Companies:<\/strong> Apic Bio, Dicerna Pharmaceuticals, Peak Bio, Arrowhead Pharmaceuticals, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Alpha-1 Antitrypsin Deficiency Therapies:<\/strong> APB-101, Belcesiran, PHP 303, ARO-AAT, and others<\/p>\n<\/li>\n<li>\n<p><strong>Alpha-1 Antitrypsin Deficiency Therapeutic Assessment:<\/strong> Alpha-1 Antitrypsin Deficiency current marketed and Alpha-1 Antitrypsin Deficiency emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Alpha-1 Antitrypsin Deficiency Market Dynamics:&nbsp; Alpha-1 Antitrypsin Deficiency market drivers and Alpha-1 Antitrypsin Deficiency market barriers&nbsp;<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Alpha-1 Antitrypsin Deficiency Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td>\n<p>1<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency- Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Late Stage Products (Phase II\/III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Preclinical Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Therapeutics Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12<\/p>\n<\/td>\n<td>\n<p>Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16&nbsp;<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18<\/p>\n<\/td>\n<td>\n<p>Alpha-1 Antitrypsin Deficiency Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=alpha1-antitrypsin-deficiency-pipeline-dynamics-2024-fda-approvals-therapeutic-advances-moa-roa-by-delveinsight-apic-bio-dicerna-pharma-peak-bio-arrowhead-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=alpha1-antitrypsin-deficiency-pipeline-dynamics-2024-fda-approvals-therapeutic-advances-moa-roa-by-delveinsight-apic-bio-dicerna-pharma-peak-bio-arrowhead-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alpha-1 Antitrypsin Deficiency pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. &ldquo;Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2024&#8220; report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/alpha1-antitrypsin-deficiency-pipeline-dynamics-2024-fda-approvals-therapeutic-advances-moa-roa-by-delveinsight-apic-bio-dicerna-pharma-peak-bio-arrowhead-pharma_716635.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-716635","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/716635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=716635"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/716635\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=716635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=716635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=716635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}